Home / 2019 / May / 09

Daily Archives: May 9, 2019

Philips announces collaboration with Medtronic to further advance the image-guided treatment of atrial fibrillation

May 9, 2019

Philips’ integrated solution will combine the unique KODEX-EPD dielectric imaging and navigation system, dielectric imaging sensors, clinical software, and services to support cryoablation procedures performed with the Medtronic Arctic Front Advancecryoablation technology

Amsterdam, The Netherlands Royal Philips (NYSE: PHG, AEX: PHIA) today announced a collaboration with Medtronic to further advance treatment of paroxysmal atrial fibrillation (PAF), a common heart rhythm disorder. Through the agreement, Medtronic will facilitate sales of products on behalf of Philips to provide an innovative, integrated image guidance solution for cryoablation procedures. Philips will bring to market the novel KODEX-EPD cardiac imaging and navigation system with cryoablation specific features to enable electrophysiologists to perform cryoablation procedures with reduced need for X-ray imaging.

Atrial fibrillation (AF) affects more than 33 million people worldwide [1]. Cryoballoon ablation is used in a minimally invasive procedure to isolate the pulmonary veins, which are a source of erratic electrical signals that cause AF. The technology uses cold energy rather than heat (radio frequency (RF) ablation) to create scar tissue and interrupt these irregular electrical pathways in the heart.

“This integrated solution can guide physicians during the treatment of AF patients with ablation, as they can view detailed, CT-like 3D anatomy, reducing the need for X-ray imaging,” said Marlou Janssen, Business Leader Philips EPD Solutions. “Partnering with Medtronic extends the reach of our KODEX-EPD cardiac imaging and navigation system. Today, this technology is simplifying navigation, and in the future it has potential for a wide range of applications, including addressing the key unmet need of real-time therapy assessment – one of the more significant limitations of the current standard of care.”

“When available, physicians will have the ability to use an innovative cardiac imaging and  mapping system during cryoablation procedures, while also realizing the significant benefits of our best-in-class cryoablation therapy,” said Rebecca Seidel, vice president and general manager of the Atrial Fibrillation Solutions division, which is part of the Cardiac and Vascular Group at Medtronic. “AF is a growing epidemic and we are committed to providing solutions to electrophysiologists that help address the needs of their patients.”

Philips’ KODEX-EPD system uses dielectric imaging to create CT-like 3D, high-definition images of a patient’s cardiac structures in real time [2]. A completely new approach to imaging the heart, dielectric imaging offers many benefits in comparison to current approaches, for both cryo and RF ablation procedures. The technology provides real-time 3D imaging, reducing the need for X-ray imaging. It also has mapping capabilities without the need to reset a reference point if the patient moves. As a result, the KODEX-EPD system provides excellent visualization and simplifies navigation, enhancing procedure efficiency and patient care.

In pulmonary vein isolation (PVI) cryoablation procedures, the system confirms the positioning of the Medtronic Achieve™ Mapping Catheter, supporting quick visualization of the pulmonary veins. Philips is also developing balloon visualization capabilities for the KODEX-EPD system.

KODEX-EPD is CE marked and has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for mapping and navigation during arrhythmia ablation procedures. KODEX-EPD systems are in clinical use at limited sites worldwide. The integrated solution to support cryoablation procedures is intended to be available for sale in the U.S. and Europe in Q4 2019.

[1] Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014; 129:837-847.
[2] Maurer T, Kuck K-H et al. First clinical experience in high-resolution imaging of left atrial anatomy using a novel wide-band dielectric mapping system. Clin Res Cardiol 108, Suppl 1, April 2019.

For further information, please contact:

Mark Groves
Philips Group Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com
Twitter: FC_Feer

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Philips Annual General Meeting of Shareholders re-appoints CEO Frans van Houten and CFO Abhijit Bhattacharya

May 9, 2018

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that today’s Annual General Meeting of Shareholders (AGM) re-appointed Frans van Houten as President/CEO and member of the Board of Management, and Abhijit Bhattacharya as member of the Board of Management fulfilling the role of CFO.

The other proposals voted on at the AGM, including the re-appointment of David Pyott and the appointment Elizabeth Doherty as members of the Supervisory Board, and the distribution of a dividend of EUR 0.85 per share over 2018, were also adopted. More information about the optional dividend can be found via this link.

Additional information on the composition of the Board of Management, the Executive Committee and the Supervisory Board can be found here.

Philips’ 2018 results are included in Philips’ 2018 Annual Report that was published on February 26, 2019.

For more information about Philips’ 2019 AGM, please click on this link.

For further information, please contact:

Ben Zwirs
Philips Group Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Ksenija Gonciarenko
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: ksenija.gonciarenko@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

WillScot Announces $190 Million Tack-On Offering of Senior Secured Notes

BALTIMORE, May 09, 2019 (GLOBE NEWSWIRE) — WillScot Corporation (“WillScot”) (Nasdaq: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that its indirect subsidiary, Williams Scotsman International, Inc. (the “Issuer”), proposes to offer up to $190 million in aggregate principal amount of its 6.875% senior secured notes due 2023 (the “New Notes”) in a private placement transaction to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to certain investors outside the United States in accordance with Regulation S under the Securities Act (the “Tack-On Offering”). The New Notes will be issued as additional securities under an Indenture, dated August 6, 2018 (as supplemented from time to time, the “Indenture”), pursuant to which the Issuer issued $300,000,000 in aggregate principal amount of its 6.875% Senior Notes due 2023 (the “Existing Notes”) in August 2018. The New Notes and the Existing Notes are intended to be treated as a single class of debt securities under the Indenture, and the New Notes will have identical terms to the Existing Notes, other than with respect to the issue date and issue price.

WillScot intends to use the net proceeds from the Tack-On Offering to repay a portion of outstanding borrowings under its senior secured revolving credit facility, which will be available to be re-borrowed in the future, subject to certain conditions.

The New Notes will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  This press release does not constitute an offer to sell any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer or sale would be unlawful.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although WillScot believes that these forward-looking statements are based on reasonable assumptions, it can give no assurance that any such forward-looking statement will materialize. Important factors that may affect actual results or outcomes include, among others: our ability to acquire and integrate assets and operations; our ability to achieve planned synergies; our ability to manage growth and execute our business plan; our estimates of the size of the markets for our products; the rate and degree of market acceptance of our products; the success of other competing modular space and portable storage solutions that exist or may become available; rising costs adversely affecting our profitability (including cost increases resulting from tariffs); potential litigation involving our company; general economic and market conditions impacting demand for our products and services; implementation of tax reform; our ability to implement and maintain an effective system of internal controls; and such other risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K for the year ending December 31, 2018 and our Form 10-Q for the quarter ended March 31, 2019). Any forward-looking statement speaks only at the date which it is made, and WillScot disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the Nasdaq stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, its fleet comprises nearly 160,000 modular space and portable storage units managed through its network of over 120 locations.

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com

Media Inquiries:

Scott Junk
scott.junk@willscot.com

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai

Lugano, Switzerland, and Beijing, China, May 9, 2019: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the Chinese market leader of pain management, today announce the availability of ALOXI® IV in China.

This is Helsinn’s first cancer supportive care product to be launched in the Chinese market, and for which Mundipharma China Pharmaceutical has exclusive marketing, promotion and sales rights. This product was approved by the National Medical Products Administration (NMPA) in November 2018.

The launch of ALOXI® IV in China, has also seen the initiation of a long co-detailing collaboration with Helsinn Pharmaceuticals (Beijing) Co., Ltd. in the municipality of Shanghai for ALOXI® IV and other future cancer care products in the Chinese market.
Andrea Meoli, Helsinn Group Chief Commercial Officer, commented: “ALOXI® IV is the first cancer supportive care product that we make available to Chinese patients. Since its launch in the other countries, ALOXI® has been effectively used for the prevention of CINV, helping to define the standard of care for the condition, and we are delighted that it is now becoming available to patients in China. We are pleased to be collaborating with Mundipharma China Pharmaceutical, a strategic partner, in introducing this product in China and co-detailing it in Shanghai and thereby helping patients in China to benefit from this treatment option.”

“The Launch of ALOXI® IV identifies expansion of strategic cooperation between Helsinn and Mundipharma China Pharmaceutical.” Said Peter Wang, General Manager, Mundipharma Pharmaceutical Greater China, “I believe there will be more CINV products with cutting-edge technologies to be brought into China market through the joint efforts of both sides, which will benefit more Chinese cancer patients.”

END

About ALOXI® (palonosetron HCI)

For China:

ALOXI® injection 0.25 mg/5 ml was approved on November 8th, 2018 in China and is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. It is also indicated in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

About Mundipharma China Pharmaceutical

Mundipharma China Pharmaceutical was established in the year of 1993 and has been dedicated to the organic growth of the pain segment in China for decades. “Bring More to Life” is our aspiration; caring for lives and serving the society is our social responsibilities. Innovation, patient-centric, and entrepreneurship are in our DNAs.

In the future, Mundipharma China will continue to explore in pain management field and expand its business into new fields, including CINV, transplantation immunology, oncology, respiratory, consumer health and etc. We’ll make unremitting efforts to providing innovative products and fulfilling our social responsibilities, ultimately to realize our vision of “Bring More to Life”.

For more information, please refer to: http://www.mundipharma.com.cn

For more information:

Helsinn Group Media Contact:

Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Email: Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on TwitterLinkedIn and Vimeo.

Mundipharma China Pharmaceutical Contact:

Kylie Gao,
PR Director
Beijing, China
Tel: +86(10) 6563 6785
Email: kylie.gao@mundipharma.com.cn

Smart Global to help boost malaysia’s highly skilled workforce

BUTTERWORTH, SMART Global Holdings, a specialty memory and storage solutions manufacturer headquartered in California, aims to contribute to Malaysia’s aspiration of increasing its pool of highly-skilled workforce from the present 18 per cent to 35 per cent.

The group, which employs about 500 people for its Malaysian operation, plans to increase its workforce here by 10 to 15 per cent within a year, SMART Modular Technologies Sdn Bhd general manager Vejay Kumar told Bernama after a media briefing and tour of the company’s manufacturing facility at Seberang Jaya here.

SMART Global Holdings executive vice president Jack Pacheco, who was in Malaysia for the briefing, said the latest industrial revolution would allow for higher productivity and efficiency in the manufacturing industry but at the same time require a well-trained and prepared workforce competent to adopt agile, innovative and game-changing technologies.

Pacheco, who is also the SMART Global Holdings chief operating and financial officer, announced the company’s partnership with computer hardware company IBM Malaysia to transform its manufacturing operations to meet the demands of the evolving technology landscape.

He noted that based on the 2019 International Data Corporation report, the nation’s gross domestic product relied heavily on high-tech manufacturing, and digital transformation could potentially add US$10 billion (RM41.5 billion) to the Malaysian economy by 2021.

Digital Malaysia, the government’s economic development programme to position Malaysia as a leading digital economy player, encourages manufacturers to leverage new manufacturing tools and skills to reap the economic benefits of the fourth industrial revolution, he said.

Meanwhile, IBM Malaysia managing director Catherine Lian said IBM’s role in the partnership included the delivery of IBM Enterprise Design Thinking workshops to upskill and reskill SMART’s workforce, as well as the development of factory automation through AI-powered, collaborative robots (cobots) to enhance human abilities.

She said that the cobots are programmed by IBM PowerAI Vision, which included an intuitive toolset that empowered subject matter expert to label, train, and deploy deep learning vision models without coding or deep learning expertise.

By deploying cobots, we aim to take human error out of the equation and to maximise cost-efficiency and business outcome, she said.

Lian said cobots were programmed to collaborate with humans by enhancing the manufacturing industry’s production efficiency, but they would not completely replace humans.

In terms of collaboration with robots, we believe the intention of using cobots is to enable humans to thrive and its augmentation is meant to enable human abilities, she added.

Source: BERNAMA (News Agency)

Smart Global to help boost malaysia’s highly skilled workforce

BUTTERWORTH, SMART Global Holdings, a specialty memory and storage solutions manufacturer headquartered in California, aims to contribute to Malaysia’s aspiration of increasing its pool of highly-skilled workforce from the present 18 per cent to 35 per cent.

The group, which employs about 500 people for its Malaysian operation, plans to increase its workforce here by 10 to 15 per cent within a year, SMART Modular Technologies Sdn Bhd general manager Vejay Kumar told Bernama after a media briefing and tour of the company’s manufacturing facility at Seberang Jaya here.

SMART Global Holdings executive vice president Jack Pacheco, who was in Malaysia for the briefing, said the latest industrial revolution would allow for higher productivity and efficiency in the manufacturing industry but at the same time require a well-trained and prepared workforce competent to adopt agile, innovative and game-changing technologies.

Pacheco, who is also the SMART Global Holdings chief operating and financial officer, announced the company’s partnership with computer hardware company IBM Malaysia to transform its manufacturing operations to meet the demands of the evolving technology landscape.

He noted that based on the 2019 International Data Corporation report, the nation’s gross domestic product relied heavily on high-tech manufacturing, and digital transformation could potentially add US$10 billion (RM41.5 billion) to the Malaysian economy by 2021.

Digital Malaysia, the government’s economic development programme to position Malaysia as a leading digital economy player, encourages manufacturers to leverage new manufacturing tools and skills to reap the economic benefits of the fourth industrial revolution, he said.

Meanwhile, IBM Malaysia managing director Catherine Lian said IBM’s role in the partnership included the delivery of IBM Enterprise Design Thinking workshops to upskill and reskill SMART’s workforce, as well as the development of factory automation through AI-powered, collaborative robots (cobots) to enhance human abilities.

She said that the cobots are programmed by IBM PowerAI Vision, which included an intuitive toolset that empowered subject matter expert to label, train, and deploy deep learning vision models without coding or deep learning expertise.

By deploying cobots, we aim to take human error out of the equation and to maximise cost-efficiency and business outcome, she said.

Lian said cobots were programmed to collaborate with humans by enhancing the manufacturing industry’s production efficiency, but they would not completely replace humans.

In terms of collaboration with robots, we believe the intention of using cobots is to enable humans to thrive and its augmentation is meant to enable human abilities, she added.

Source: BERNAMA (News Agency)

Smart Global to help boost malaysia’s highly skilled workforce

BUTTERWORTH, SMART Global Holdings, a specialty memory and storage solutions manufacturer headquartered in California, aims to contribute to Malaysia’s aspiration of increasing its pool of highly-skilled workforce from the present 18 per cent to 35 per cent.

The group, which employs about 500 people for its Malaysian operation, plans to increase its workforce here by 10 to 15 per cent within a year, SMART Modular Technologies Sdn Bhd general manager Vejay Kumar told Bernama after a media briefing and tour of the company’s manufacturing facility at Seberang Jaya here.

SMART Global Holdings executive vice president Jack Pacheco, who was in Malaysia for the briefing, said the latest industrial revolution would allow for higher productivity and efficiency in the manufacturing industry but at the same time require a well-trained and prepared workforce competent to adopt agile, innovative and game-changing technologies.

Pacheco, who is also the SMART Global Holdings chief operating and financial officer, announced the company’s partnership with computer hardware company IBM Malaysia to transform its manufacturing operations to meet the demands of the evolving technology landscape.

He noted that based on the 2019 International Data Corporation report, the nation’s gross domestic product relied heavily on high-tech manufacturing, and digital transformation could potentially add US$10 billion (RM41.5 billion) to the Malaysian economy by 2021.

Digital Malaysia, the government’s economic development programme to position Malaysia as a leading digital economy player, encourages manufacturers to leverage new manufacturing tools and skills to reap the economic benefits of the fourth industrial revolution, he said.

Meanwhile, IBM Malaysia managing director Catherine Lian said IBM’s role in the partnership included the delivery of IBM Enterprise Design Thinking workshops to upskill and reskill SMART’s workforce, as well as the development of factory automation through AI-powered, collaborative robots (cobots) to enhance human abilities.

She said that the cobots are programmed by IBM PowerAI Vision, which included an intuitive toolset that empowered subject matter expert to label, train, and deploy deep learning vision models without coding or deep learning expertise.

By deploying cobots, we aim to take human error out of the equation and to maximise cost-efficiency and business outcome, she said.

Lian said cobots were programmed to collaborate with humans by enhancing the manufacturing industry’s production efficiency, but they would not completely replace humans.

In terms of collaboration with robots, we believe the intention of using cobots is to enable humans to thrive and its augmentation is meant to enable human abilities, she added.

Source: BERNAMA (News Agency)